After the development of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), one of the unmet needs in the treatment of hormone receptor-positive (HR+) advanced breast cancer (ABC) was to find therapies that could provide meaningful benefit beyond progression due to the relative chemoresistance of these tumors. This evidence concerns the gene CDK4 and breast cancer.